Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-23
MYLAN
Dec-18
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0723,975-   
Low Rs7902,188-   
Sales per share (Unadj.) Rs182.91,829.1-  
Earnings per share (Unadj.) Rs35.749.7-  
Cash flow per share (Unadj.) Rs46.2392.1-  
Dividends per share (Unadj.) Rs11.500-  
Avg Dividend yield %1.20-  
Book value per share (Unadj.) Rs233.41,978.8-  
Shares outstanding (eoy) m2,399.34514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.11.7 302.1%   
Avg P/E ratio x26.162.0 42.0%  
P/CF ratio (eoy) x20.17.9 256.3%  
Price / Book Value ratio x4.01.6 256.1%  
Dividend payout %32.20-   
Avg Mkt Cap Rs m2,233,3611,585,442 140.9%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m82,9600-   
Avg. sales/employee Rs Th026,887.8-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.1-  
INCOME DATA
Net Sales Rs m438,857941,074 46.6%  
Other income Rs m8,1990-   
Total revenues Rs m447,055941,074 47.5%   
Gross profit Rs m112,900243,515 46.4%  
Depreciation Rs m25,294176,206 14.4%   
Interest Rs m1,72045,262 3.8%   
Profit before tax Rs m94,08422,047 426.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,476-3,507 -241.7%   
Profit after tax Rs m85,60825,554 335.0%  
Gross profit margin %25.725.9 99.4%  
Effective tax rate %9.0-15.9 -56.6%   
Net profit margin %19.52.7 718.4%  
BALANCE SHEET DATA
Current assets Rs m398,619525,495 75.9%   
Current liabilities Rs m199,064383,144 52.0%   
Net working cap to sales %45.515.1 300.6%  
Current ratio x2.01.4 146.0%  
Inventory Days Days14784 175.9%  
Debtors Days Days9593 102.0%  
Net fixed assets Rs m376,960182,553 206.5%   
Share capital Rs m2,399501 478.8%   
"Free" reserves Rs m557,5550-   
Net worth Rs m559,9541,018,070 55.0%   
Long term debt Rs m01,098,825 0.0%   
Total assets Rs m775,7942,730,861 28.4%  
Interest coverage x55.71.5 3,745.6%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.60.3 164.2%   
Return on assets %11.32.6 434.1%  
Return on equity %15.32.5 609.1%  
Return on capital %17.13.2 538.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m82,5410-   
CASH FLOW
From Operations Rs m49,593195,555 25.4%  
From Investments Rs m-79,437-101,081 78.6%  
From Financial Activity Rs m23,761-91,101 -26.1%  
Net Cashflow Rs m1,1551,620 71.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: PLETHICO PHARMA  KREBS BIOCHEMICALS  FABINO LIFE   NECTAR LIFESCIENCE  SMS LIFESCIENCES INDIA  



Today's Market

Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling(Closing)

After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.